Stocks News

LAST PRICE
40.0000
TODAY'S CHANGE (%)
Trending Up0.5300 (1.3428%)

Bid / Lots
39.1700/ 1
Ask / Lots
41.6300/ 1
Open / Previous Close
39.6400 / 39.4700
Day Range
Low 39.6400
High 40.1400
52 Week Range
Low 35.8144
High 49.1753
Volume
1,107,980
above average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Apr 9, 2024
- QIAGEN N.V. to release results for Q1 2024 and hold webcast, from 9:48AM ET on Tuesday Apr 09, 2024 by Dow Jones
  9:48AM ET on Tuesday Apr 09, 2024 by Dow Jones
  Companies Mentioned: QGEN
  
  QIAGEN N.V. to release results for Q1 2024 and hold webcast
  
  Venlo, The Netherlands, April 09, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2024.
Apr 3, 2024
- QIAGEN strengthens its portfolio for cancer research, showcasing latest product launches at AACR Annual Meeting 2024, from 4:05PM ET on Wednesday Apr 03, 2024 by GlobeNewswire
  4:05PM ET on Wednesday Apr 03, 2024 by GlobeNewswire
  Companies Mentioned: QGEN
- QIAGEN strengthens its portfolio for cancer research, showcasing latest product launches at AACR Annual Meeting 2024, from 4:05PM ET on Wednesday Apr 03, 2024 by Dow Jones
  4:05PM ET on Wednesday Apr 03, 2024 by Dow Jones
  Companies Mentioned: QGEN
  
  or transportation delays, natural disasters, political or public health crises, and its impact on the demand for our products and other aspects of our business, or other force majeure events; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading "Risk Factors" contained in Item 3 of our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.
Mar 25, 2024
- QIAGEN introduces QIAstat-Dx Analyzer 2.0 with remote test results access, enhancing collaboration across healthcare system, from 4:05PM ET on Monday Mar 25, 2024 by GlobeNewswire
  4:05PM ET on Monday Mar 25, 2024 by GlobeNewswire
  Companies Mentioned: QGEN
- QIAGEN introduces QIAstat-Dx Analyzer 2.0 with remote test results access, enhancing collaboration across healthcare system, from 4:05PM ET on Monday Mar 25, 2024 by Dow Jones
  4:05PM ET on Monday Mar 25, 2024 by Dow Jones
  Companies Mentioned: QGEN
  
  QIAGEN introduces QIAstat-Dx Analyzer 2.0 with remote test results access, enhancing collaboration across healthcare system
  
  QIAstat-Dx Analyzer 2.0 with Software 1.6 release enables mobile access to test results, streamlining diagnostic processes and enhancing patient care // QIAstat-Dx Analyzer 2.0 also offers enhanced epidemiology dashboards and improved remote system management // Growing global presence: Over 4,000 QIAstat-Dx instruments for reliable, fast and cost--effective diagnosis of complex syndromes placed worldwide by the end of 2023

Today
- United Therapeutics Insider Sold Shares Worth $1,704,990, According to a Recent SEC Filing, from 5 hours ago by MT Newswires
  5 hours ago by MT Newswires
  Companies Mentioned: UTHR
Apr 17, 2024
- United Therapeutics Insider Sold Shares Worth $1,682,819, According to a Recent SEC Filing, from 4:40PM ET on Wednesday Apr 17, 2024 by MT Newswires
  4:40PM ET on Wednesday Apr 17, 2024 by MT Newswires
  Companies Mentioned: UTHR
Apr 16, 2024
- Neurocrine Biosciences, Sentia Medical Sciences Extend Partnership on Prospective Drug Development, from 4:32PM ET on Tuesday Apr 16, 2024 by MT Newswires
  4:32PM ET on Tuesday Apr 16, 2024 by MT Newswires
  Companies Mentioned: NBIX
- United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International Conference, from 7:00AM ET on Tuesday Apr 16, 2024 by Business Wire
  7:00AM ET on Tuesday Apr 16, 2024 by Business Wire
  Companies Mentioned: UTHR
Apr 15, 2024
- United Therapeutics Insider Sold Shares Worth $1,707,775, According to a Recent SEC Filing, from 4:37PM ET on Monday Apr 15, 2024 by MT Newswires
  4:37PM ET on Monday Apr 15, 2024 by MT Newswires
  Companies Mentioned: UTHR
Apr 11, 2024
- United Therapeutics Insider Sold Shares Worth $6,831,737, According to a Recent SEC Filing, from 4:36PM ET on Thursday Apr 11, 2024 by MT Newswires
  4:36PM ET on Thursday Apr 11, 2024 by MT Newswires
  Companies Mentioned: UTHR
- Barclays Downgrades Exelixis to Equalweight From Overweight, Price Target is $25, from 9:40AM ET on Thursday Apr 11, 2024 by MT Newswires
  9:40AM ET on Thursday Apr 11, 2024 by MT Newswires
  Companies Mentioned: EXEL
Apr 9, 2024
- United Therapeutics Insider Sold Shares Worth $4,727,736, According to a Recent SEC Filing, from 4:40PM ET on Tuesday Apr 09, 2024 by MT Newswires
  4:40PM ET on Tuesday Apr 09, 2024 by MT Newswires
  Companies Mentioned: UTHR
Apr 8, 2024
- Morgan Stanley Lifts Price Target on Neurocrine Biosciences to $160 From $150, Sees Upside to Shares Ahead of Mid-Stage Readouts; Overweight Kept, from 7:07AM ET on Monday Apr 08, 2024 by MT Newswires
  7:07AM ET on Monday Apr 08, 2024 by MT Newswires
  Companies Mentioned: NBIX
Apr 5, 2024
- United Therapeutics Insider Sold Shares Worth $6,957,709, According to a Recent SEC Filing, from 4:40PM ET on Friday Apr 05, 2024 by MT Newswires
  4:40PM ET on Friday Apr 05, 2024 by MT Newswires
  Companies Mentioned: UTHR

Qiagen NV
NYSE:QGENUnited States

Search Criteria

Apr 9, 2024

QIAGEN N.V. to release results for Q1 2024 and hold webcast, from 9:48AM ET on Tuesday Apr 09, 2024 by Dow Jones

Apr 3, 2024

QIAGEN strengthens its portfolio for cancer research, showcasing latest product launches at AACR Annual Meeting 2024, from 4:05PM ET on Wednesday Apr 03, 2024 by GlobeNewswire

QIAGEN strengthens its portfolio for cancer research, showcasing latest product launches at AACR Annual Meeting 2024, from 4:05PM ET on Wednesday Apr 03, 2024 by Dow Jones

Mar 25, 2024

QIAGEN introduces QIAstat-Dx Analyzer 2.0 with remote test results access, enhancing collaboration across healthcare system, from 4:05PM ET on Monday Mar 25, 2024 by GlobeNewswire

QIAGEN introduces QIAstat-Dx Analyzer 2.0 with remote test results access, enhancing collaboration across healthcare system, from 4:05PM ET on Monday Mar 25, 2024 by Dow Jones

Peers Headlines

Today

United Therapeutics Insider Sold Shares Worth $1,704,990, According to a Recent SEC Filing, from 5 hours ago by MT Newswires

Apr 17, 2024

United Therapeutics Insider Sold Shares Worth $1,682,819, According to a Recent SEC Filing, from 4:40PM ET on Wednesday Apr 17, 2024 by MT Newswires

Apr 16, 2024

Neurocrine Biosciences, Sentia Medical Sciences Extend Partnership on Prospective Drug Development, from 4:32PM ET on Tuesday Apr 16, 2024 by MT Newswires

United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International Conference, from 7:00AM ET on Tuesday Apr 16, 2024 by Business Wire

Apr 15, 2024

United Therapeutics Insider Sold Shares Worth $1,707,775, According to a Recent SEC Filing, from 4:37PM ET on Monday Apr 15, 2024 by MT Newswires

Apr 11, 2024

United Therapeutics Insider Sold Shares Worth $6,831,737, According to a Recent SEC Filing, from 4:36PM ET on Thursday Apr 11, 2024 by MT Newswires

Barclays Downgrades Exelixis to Equalweight From Overweight, Price Target is $25, from 9:40AM ET on Thursday Apr 11, 2024 by MT Newswires

Apr 9, 2024

United Therapeutics Insider Sold Shares Worth $4,727,736, According to a Recent SEC Filing, from 4:40PM ET on Tuesday Apr 09, 2024 by MT Newswires

Apr 8, 2024

Morgan Stanley Lifts Price Target on Neurocrine Biosciences to $160 From $150, Sees Upside to Shares Ahead of Mid-Stage Readouts; Overweight Kept, from 7:07AM ET on Monday Apr 08, 2024 by MT Newswires

Apr 5, 2024

United Therapeutics Insider Sold Shares Worth $6,957,709, According to a Recent SEC Filing, from 4:40PM ET on Friday Apr 05, 2024 by MT Newswires